Navigation Links
Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer

NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that a first line Phase III study of ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall survival in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The randomized, multi-center study, known as EXTREME, studied more than 400 patients treated with ERBITUX in combination either with cisplatin plus 5-fluorouracil (5-FU) or carboplatin plus 5-FU, compared to patients treated with cisplatin plus 5-FU or carboplatin plus 5-FU alone.

"We are excited by the results of this study, as it is the first large, randomized clinical trial to examine the impact of ERBITUX treatment in combination with platinum-based chemotherapy on overall survival in metastatic head and neck cancer," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "ERBITUX has already demonstrated improved survival when combined with radiation in locoregionally advanced head and neck cancer."

"When ERBITUX was approved for head and neck cancer, it was not only hailed as the first new treatment for the disease in 45 years, but it was also the first drug approved to show a survival benefit in this population. Just one year later, this study adds to the growing body of clinical evidence with ERBITUX in these patients," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affairs, Bristol-Myers Squibb.

Results from this study have been submitted for presentation at the 2007 American Society of Clinical Oncology Annual Meeting in Chicago, June.

About Head and Neck Cancer

According to the American Cancer Society, 81,550 Americans will be diagnosed with head and neck cancer in 2007, including cancers of the tongue, the rest of th
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
(Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... Research and Markets has announced ... Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the aspects ... and business performance of domestic major enterprises, as well ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... INDIANAPOLIS, Oct. 11, 2011 Eli Lilly and ... due to the December 31 retirements of longtime senior leaders, ... whose Lilly career spans 36 years, has led Lilly Bio-Medicines ... Lilly spans 33 years, has led global manufacturing operations since ...
... 2011 MedPro Imaging, a premium provider of new and ... transducer repair capabilities to include GE E8/E9 transducers.  MedPro is ... probes for the GE E8/E9 ultrasound systems and has been ... care systems for the past six months. In ...
Cached Medicine Technology:Lilly Announces Changes in Senior Management 2Lilly Announces Changes in Senior Management 3Lilly Announces Changes in Senior Management 4MedPro Imaging to Repair GE E8/E9 Ultrasound Transducers 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 After ... the country for the past several years, Dr. ... Hyperbaric Center have announced a scholarship program for ... announcement follows a meeting held this summer to ... recent years, reporters have shed light on the ...
(Date:8/30/2014)... 30, 2014 Insomnia causes disturbances in every ... how they unknowingly developed insomnia and the steps often used ... Tune in to the show at this link: ... live on August 30, and will be podcasted at ... go to DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized ...
(Date:8/30/2014)... "My wife suffered neck, back and spine ... one of two inventors from Bethel, Alaska. "The whiplash ... neck area. She tried other pillows to little avail. ... in comfort and providing extra sleep." , They created ... the head, neck and back comfortably. This enables the ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's ... Labor Day discount on all SEO services. While working ... services related to internet marketing. Their dedicated team of ... do have a deep understanding for their specialization. This ... and since the inception, they have worked with over ...
(Date:8/30/2014)... 2014 In today’s world, a good ... to get. Snoring and sleep apnea (a medical problem ... robs people and their bed partners of the rest ... 45% of the population snores and 20 million people ... these, only 10% have been diagnosed and treated; and ...
Breaking Medicine News(10 mins):Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Josh Kelley, analyst with,HealthLeaders-InterStudy, a leading provider of ... Bill Richardson,s healthcare,reform proposal in light of a ... 15. Gov. Richardson called the session following the ... budget surplus in New,Mexico., Mr. Kelley ...
... 6 Mylan Inc. (NYSE: MYL ),announced ... Famy Care Ltd, a,global, India-based manufacturing leader of ... oral contraceptive (OC) medicines to customers in,the United ... right of first,refusal for additional oral contraceptive products ...
... Full Year Revenue Guidance to a range of $410 Million to $420 ... Million ... of $109.8 million, up 57.5% over second quarter 2007 - Gross profit of $27.4 million, up ... 23.5% ...
... quarter ... up 79% from second quarter 2007, - Second quarter operating margin of 12.7%, up 160 bp from second quarter ... 2007, - Record new business awards of $204 million, up 24% from second quarter ... 2007, - Record total business authorizations of $979 million, up 13% from Dec. ...
... of Internet-based medical billing software for physician offices, hospitalists and ... ten participants. , ... Orlando, FL ... Internet-based http://www.collaboratemd.com/ [medical billing software] for physician offices, ...
... Explore the Evolution of Vulnerability Management and Operational Whitelisting ... , ... Scottsdale, ... [Lumension Security™ Inc. __title__ Vulnerability Management Solutions], a recognized, ...
Cached Medicine News:Health News:Mylan Creates New Women's Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products 2Health News:Mylan Creates New Women's Health Care Franchise; Signs Agreement with Famy Care to Develop and Supply 22 Oral Contraceptive Products 3Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 2Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 3Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 4Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 5Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 6Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 7Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 8Health News:Symmetry Medical Reports Record Second Quarter 2008 Revenue of $109.8 Million 9Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 2Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 3Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 4Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 5Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 6Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 7Health News:Kendle Delivers Record Sales, Net Service Revenues and Earnings Per Share for Second Quarter 2008 8Health News:CollaborateMD Launches New Value-Added Reseller (VAR) Program 2Health News:Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast 2Health News:Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast 3
... of P.falciparum specific histidine ... specific pLDH and pan malaria ... of P. falciparum and ... other malarial species and for the ...
... a two site sandwich immunoassay ... detection of P. falciparum specific ... and P. vivax specific pLDH. ... used for specific detection and ...
Malaria Pf. Assay Range...
ADVANTAGE MALARIA STIX is a visual, rapid and sensitive immunoassay for the qualitative differential detection of P.falciparum (P.f) and P.vivax (P.v) malaria in Human Blood only....
Medicine Products: